Verrica Pharmaceuticals Inc. (VRCA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Jayson M. Rieger M.B.A., Ph.D.
|
President, CEO & Director | 391.17k | -- | 1976 |
|
Mr. John J. Kirby CPA
|
Interim Chief Financial Officer | 532.5k | -- | 1972 |
|
Dr. Noah L. Rosenberg M.D.
|
Chief Medical Officer | 243.32k | -- | 1967 |
|
Mr. David Zawitz
|
COO, Chief Legal Officer & Secretary | -- | -- | 1981 |
|
Mr. Eugene Scavola
|
Executive Vice President of Technical Operations | -- | -- | -- |
|
Dr. Bradley J. Catalone MBA, Ph.D.
|
Head of Drug Development | -- | -- | -- |
|
Mr. Chris Chapman
|
Chief Commercial Officer | -- | -- | -- |
Verrica Pharmaceuticals Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 76
Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Corporate Governance
Upcoming Events
November 12, 2026 at 9:00 PM UTC
Verrica Pharmaceuticals Inc. Earnings Date
Recent Events
December 19, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
